These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37086630)

  • 1. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.
    Yan H; Talty R; Jain A; Cai Y; Zheng J; Shen X; Muca E; Paty PB; Bosenberg MW; Khan SA; Johnson CH
    Redox Biol; 2023 Jun; 62():102699. PubMed ID: 37086630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.
    Yan H; Talty R; Jain A; Cai Y; Zheng J; Shen X; Muca E; Paty PB; Bosenberg MW; Khan SA; Johnson CH
    bioRxiv; 2023 Mar; ():. PubMed ID: 36909561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A machine learning and drug repurposing approach to target ferroptosis in colorectal cancer stratified by sex and KRAS.
    Yan H; Shen X; Yao Y; Khan SA; Ma S; Johnson CH
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
    Zhou X; Kang J; Zhang L; Cheng Y
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):119-134. PubMed ID: 37318525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
    Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
    Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS
    Miao Q; Deng WQ; Lyu WY; Sun ZT; Fan SR; Qi M; Qiu SH; Zhu YR; Lin JP; Chen MF; Deng LJ
    Free Radic Biol Med; 2023 Aug; 204():301-312. PubMed ID: 37217090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
    Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
    BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational status of KRAS and MMR genes in a series of colorectal carcinoma cases.
    Cionca FL; Dobre M; Dobrea CM; Iosif CI; Comănescu MV; Ardeleanu CM
    Rom J Morphol Embryol; 2018; 59(1):121-129. PubMed ID: 29940619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.